rss
Gut 1999;44:226-230 doi:10.1136/gut.44.2.226
  • Colon

Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation

  1. A Attara,
  2. M Lémannb,
  3. A Fergusonl,
  4. M Halphenc,
  5. M-C Boutrona,
  6. B Flouriéa,
  7. E Alixd,
  8. M Salmerone,
  9. F Guillemotf,
  10. S Chaussadeg,
  11. A-M Ménardh,
  12. J Moreaui,
  13. G Naudinj,
  14. M Barthetk
  1. aService de Gastroentérologie, Hôpital Saint-Lazare, Paris, France, bService de Gastroentérologie, Hôpital Saint-Louis, Paris, France, cNorgine Pharma, Paris, France, dService de Gériatrie, Hôpital du Mans, France, eService de Gastroentérologie, Hôpital de La Croix-Saint-Simon, Paris, France, fService de Gastroentérologie, Hôpital Claude Huriez, Lille, France, gService de Gastroentérologie, Hôpital Cochin, Paris, France, hService de Gériatrie, Hôpital de Villiers-Le-Bel, France, iService de Gastroentérologie, Hôpital Rangueil, Toulouse, France, jService de Gastroentérologie, Hôpital des Diaconnesses, Paris, France, kService de Gastroentérologie, Hôpital Sainte-Marguerite, Marseille, France, lGastrointestinal Unit, Western General Hospital, Edinburgh, UK
  1. Dr M Lémann, Service de Gastroentérologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
  • Accepted 7 July 1998

Abstract

Background Polyethylene glycol (PEG) 3350 is a non-absorbable, non-metabolised osmotic agent used in lavage solutions for gut cleansing.

Aims To compare the efficacy of PEG and lactulose in chronic constipation.

Methods A total of 115 patients with chronic constipation entered a multicentre, randomised, comparative trial. They initially received two sachets containing either PEG (13 g/sachet) or lactulose (10 g/sachet) and were given an option to change the dose to one or three sachets/day, depending on response.

Results Ninety nine patients completed the trial. After four weeks, patients in the PEG group (n=50) had a higher number of stools and a lower median daily score for straining at stool than patients in the lactulose group (n=49). Overall improvement was greater in the PEG group. Clinical tolerance was similar in the two groups, but flatus was less frequently reported in the PEG group. The mean number of liquid stools was higher in the PEG group but the difference was significant only for the first two weeks. There were no serious adverse events and no significant change in laboratory tests in either group. At the end of the study, the number of sachets used by the patients was 1.6 (0.7)/day in the PEG group and 2.1 (0.7)/day in the lactulose group. Sixty one patients completed a further two months open study of one to three sachets PEG daily; there was no loss of efficacy and no serious toxicity.

Conclusion Low dose PEG 3350 was more effective than lactulose and better tolerated.

Footnotes

  • Abbreviations:
    PEG
    polyethylene glycol

This Article

  1. Abstract
  2. Full text
  3. PDF

Register for free content


Free trial
Individuals may register for a free 60 day online trial to all content.

Free archive
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.